A phase II study of high dose epirubicin in unresectable non small cell lung cancer.

Epirubicin (EPI), a doxorubicin analogue, is reported to have equal antitumour activity with lower cardiac and systemic toxicity. Recently, the maximum tolerated dose of this drug has been revised upwards with reported increased response rates in several malignancies. We initiated a phase II study o...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Smit, E. F., Berendsen, H. H., Piers, D. A., Smeets, J., Riva, A., Postmus, P. E.
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 1992
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC1977612/
https://ncbi.nlm.nih.gov/pubmed/1313691
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados